key: cord-0283207-191wfyzw
authors: Joslyn, Louis R.; Linderman, Jennifer J.; Kirschner, Denise E.
title: A virtual host model of Mycobacterium tuberculosis infection identifies early immune events as predictive of infection outcomes
date: 2021-11-10
journal: bioRxiv
DOI: 10.1101/2021.11.08.467840
sha: 187ca6a659818600bff9d9866bfa67401b0ded6b
doc_id: 283207
cord_uid: 191wfyzw

Tuberculosis (TB), caused by infection with Mycobacterium tuberculosis (Mtb), is one of the world’s deadliest infectious diseases and remains a significant global health burden. TB disease and pathology can present clinically across a spectrum of outcomes, ranging from total sterilization of infection to active disease. Much remains unknown about the biology that drives an individual towards various clinical outcomes as it is challenging to experimentally address specific mechanisms driving clinical outcomes. Furthermore, it is unknown whether numbers of immune cells in the blood accurately reflect ongoing events during infection within human lungs. Herein, we utilize a systems biology approach by developing a whole-host model of the immune response to Mtb across multiple physiologic and time scales. This model, called HostSim, tracks events at the cellular, granuloma, organ, and host scale and represents the first whole-host, multi-scale model of the immune response following Mtb infection. We show that this model can capture various aspects of human and non-human primate TB disease and predict that biomarkers in the blood may only faithfully represent events in the lung at early time points after infection. We posit that HostSim, as a first step toward personalized digital twins in TB research, offers a powerful computational tool that can be used in concert with experimental approaches to understand and predict events about various aspects of TB disease and therapeutics.

pulmonary TB (39,40). Other organs and body system are also involved during extrapulmonary 139 TB, including liver, brain, and other extrapulmonary sites. We believe that focusing this study on 140 pulmonary TB is without loss of generality, and that adding in those other body sites would serve 141

to fine tune our predictions to other clinical outcomes of TB. 142 143

Each virtual host includes multiple granulomas with separate parameter values, and a single 144 parameter set for the LN and blood. The assumption that granulomas within the same host have 145

separate parameter values is supported broadly by both modeling and experimental studies that 146 have shown each granuloma within a host evolves independently (9,10,25,26,29,36,41,42). 147 148

Modeling multiple lung granulomas across time -MultiGran 149 150

In a recent study, we built a novel hybrid agent-based model that describes the development of 151 multiple lung granulomas known as MultiGran (36). In this model, each granuloma acts as an 152 agent, placed stochastically within the boundary of a 3-dimensional lung environment ( Figure  153 1A). To create this 'virtual lung' we used a CT scan from an uninfected NHP (36) as the three-154 dimensional lung architecture upon which multiple granulomas develop across time (translating 155 the x,y,z coordinates from a CT scan to our computer model (36)). Simulations begin with 156 inoculation of multiple bacteria into the lung environment. A granuloma is initialized when each 157

Mtb is placed within the lung environment, as NHP studies have shown that each Mtb bacterium 158

can form a unique granuloma (9,10). 159 160 Briefly, the development of each individual granuloma "agent" is captured by a system of ODEs 161 that tracks bacterial, macrophage, T cell, and cytokine dynamics. To describe the role of the 162 innate immune response within a granuloma, we track resting, infected and activated 163 macrophages as well intracellular and extracellular bacterial populations. To capture the impact 164 of the adaptive immune system, we track primed CD4+ and CD8+ T cell populations. Primed 165 CD4+ T cells can differentiate into effector Th1 or Th2 populations and primed CD8+ T cell 166 populations can differentiate into cytotoxic or cytokine producing CD8+ T cell populations. 167 Recruitment of T cells from the blood compartment to granulomas is described in greater detail 168 below. We additionally track concentrations of pro-and anti-inflammatory cytokines within 169 each granuloma, including IFN-γ, TNF-α, IL-10, IL-4 and IL-12. MultiGran only included the 170 primed and differentiated T cell populations described above; but we now include effector 171 memory T cells to be consistent with experiments that have shown effector memory T cells are 172 present within the granuloma environment (43-45). Thus, we expanded the set of ODEs 173

representing each single granuloma in MultiGran (36) to include CD4+ and CD8+ effector 174 memory T cell subpopulations. Briefly, we assume effector memory cells are recruited from the 175 blood to granulomas according to the inflammatory profiles of granulomas (see Linking models 176 section below for further detail). Once at the site of the granuloma, effector memory cells 177 differentiate into T cells that exhibit effector functions (45-47). 178 179

Granulomas within MultiGran can sterilize bacteria, control bacterial growth over time, or 180 exhibit uncontrolled bacterial growth. Granulomas can also disseminate, spreading bacteria 181 locally or non-locally ( Figure 1A ). Local dissemination events initialize a new granuloma near 182 the disseminating granuloma whereas non-local dissemination initializes a new granuloma 183 randomly within the lung environment. Model equations and details are in the Supplementary  184 Materials, which includes a list of all parameters, definitions, and ranges. 185 186

Lymph node and blood models 187 188

In previous work, we captured LN and blood cellular dynamics following Mtb infection or 189 vaccination using a two-compartment mathematical model (26, 38, 48) . Briefly, we track specific and Mtb-non-specific CD4+ and CD8+ naïve, effector, effector memory, and central 191 memory T cell responses using a compartmentalized system of 31 non-linear ODEs ( Figure 1B) . 192 We represent Mtb-specific T cells as a generic class of antigen-specific cells across time. We also coarse-grain the process of T-cell lung-homing and migration to the sites of granulomas. 227

In HostSim, there are three types of blood T cells that are recruited to the granuloma: Mtb-228 specific effector T cells, Mtb-specific effector memory T cells, and non-specific T-cells. Note, 229 once blood Mtb-specific effector T cells arrive in the granuloma, they are considered primed T 230 cells. Recruitment occurs for both CD4+ and CD8+ T cell lineages. 231 232

Each cell type is recruited to each granuloma according to inflammatory signals within our 233 granuloma model. These include counts of activated and infected macrophages, and levels of the 234 pro-inflammatory cytokine TNF, consistent with experimental data and previously presented 235 models (25,37,54-57). We calculate the number of Mtb-specific effector T cells that will be 236 recruited from the blood to the i th granuloma, granulomai, per time step according to the 237 following equation, as outlined in our previous modeling work (33,36,58): 238 239

Where "# , % , "' , ) , +'% are granuloma-specific parameters (see Supplementary Material  245  Table 1 ). Effector Memory T cells are recruited similarly to each granuloma, but recruitment is 246 performed proportional to the level of TNF-α within the granuloma (see Effector Memory T cell 247 granuloma equations in Supplementary Material). We assume different mechanisms of 248 recruitment between these T cell phenotypes arises due to known differences in migration of 249 effector memory and effector T cells to non-lymphoid sites, such as the lung (reviewed in (58)). 250

Altogether, numbers of macrophage and inflammatory cytokine levels act as a proxy within our 251 model for chemotactic and adhesion molecules acting within a granuloma that attract T cells to 252 the site. We perform recruitment for each granuloma at every timestep within the model, i. points, such that the experimental data illustrates a heterogenous range of potential outcomes 303 (Figure 2 B, C & D). 304 305 We determined initial parameter ranges for each model parameter based on experimental values 306 from literature, as well as previous single granuloma ODE models, previous lymph node and 307 blood ODE models, and our previous work in modeling multiple granulomas (33,38,58,66). In 308 this modeling framework, some of the parameter values are constrained (such as rates of 309 bacterial killing or cellular death rates) and were not as widely varied as others. We utilized a 310

Latin hypercube sampling (LHS) scheme to sample 500 times within the initial parameter space, 311 thereby creating 500 unique simulations of HostSim (i.e. generating 500 unique virtual hosts). 312 We then use CaliPro to refine and resample this wide initial parameter space in an iterative 313 manner. 314 315

CaliPro requires users to explicitly define a pass set -this is an automated criterion for which 316 the model simulations can be considered calibrated. We specify a pass set as the simulations that 317 fall within the range bounded by an order of magnitude on either side of the minimum and 318 maximum experimental data point for every time point across each of the experimental 319 outcomes. The experimental data range includes over four orders of magnitude ( Figure 2B ), 320 therefore our pass set definition was selected since it encapsulates the general behavior of the 321 experimental datasets we are using for calibration and will not remove simulations that are 322 within the same order of magnitude as experimental data points. Additionally, we know that the 323 long-term behavior of bacterial numbers in granulomas are fairly stable without intervention (9) that total bacterial burden is associated with clinical outcomes. Specifically, total bacterial 491 burden in active TB cases is significantly higher than that of LTBI monkeys (21). HostSim 492 exhibits similarly heterogenous host-scale outcomes (Figure 3 ). 493 494

To explore ranges of host-scale outcomes in a virtual host study, we sample from our calibrated 495 parameter space to generate a virtual population of 500 unique hosts. Each simulation begins 496

with an inoculation dose of 10 CFU (selected to be consistent with inoculation of NHPs (68)), 497 thereby starting the formation of 10 individual granulomas within the lung environment. 498

Simulations run for 200 days. We calculate the total lung CFU by summing the individual 499 granuloma CFU for all granulomas within a host. 500 501

Across our virtual population of 500 virtual hosts, the total lung CFU per host spans several 502 orders of magnitude, from 0 CFU (infection elimination) to 10 6 CFU ( Figure 3A ). We delineate 503 our virtual population into 3 groups according to their total lung CFU at day 200, analogous to 504 the clinical classifications of NHPs 6-8 months following primary infection (69) . We use the 505 following cutoffs for classification: TB eliminators: total lung CFU<1; Active TB cases: total 506 lung CFU > 10 5 ; LTBI: all other virtual hosts. Across our 500 virtual hosts, there are 24 TB 507 eliminators, 110 active TB cases, and 366 LTBI individuals. Snapshots from representative 508 simulations of these diverse outcomes are displayed in Figure 3D , 3E & 3F. 509 510

After classifying the virtual hosts by total lung CFU, we looked at two additional statistics. First, 511

we examined the number of sterilized granulomas across the three different clinical 512 classifications ( Figure 3B ). Our model predicts that ~75% of active TB cases include at least one 513 sterile granuloma. This finding is validated by a previously published NHP dataset, which 514

showed 11 out of 13 monkeys with active TB had at least a single sterilized granuloma (9). 515 516

Second, we looked at the number of virtual hosts that have individual granulomas with a high 517 bacterial burden (defined as granulomas with 5x10 4 CFU or higher; Figure 3C ). As expected, all 518 TB eliminators and the majority of LTBI virtual hosts do not contain a granuloma with a high 519 bacterial burden. However, we see approximately 8% of our LTBI classified hosts include one 520 high CFU granuloma. These cases indicate that our model may have the potential to capture 521 incident or subclinical TB and may explain the spectrum nature of TB disease as these 522

individuals could be more likely to reactivate or progress to active disease (5). 523 524 525 526 527 Fig 3: HostSim exhibits a spectrum of whole-host outcomes across a population of 500 A multi-scale sensitivity analysis reveals adaptive immunity drives clinical classification and 538

innate immunity impacts granuloma-scale outcomes 539 540

We next use the model to investigate mechanisms that drive host-scale clinical outcomes. Using 541 uncertainty and sensitivity analysis, we can identify these driving mechanisms across multiple 542 scales of interest. First, we perform an 'all-in-one' sensitivity analysis (see Methods) on clinical  543 classifications (see Figure 3 ) across the 500 virtual hosts from our calibrated parameter space. 544 Table 1 highlights parameters found to be significantly correlated (p<0.05) with each clinical 545 classification from our PRCC analysis. Not surprisingly, we find that elements of adaptive 546

immune responses within LNs are main drivers of whole-host clinical outcomes. Specifically, the 547 differentiation and proliferation of T cells within LNs are significantly associated with clinical 548 scale outcomes (i.e. active TB, LTBI or TB eliminator). The significant, positive association 549

between T-cell proliferation in LN and clinical classification at the whole-host scale represents 550 an inter-physiologic compartmental effect -not only do LN parameters influence T-cell counts 551

within the LN, but they influence whole-host scale clinical outcomes as well. Further, both Mtb-552 specific CD4+ and Mtb-specific CD8+ T cell parameters in the LN impact clinical-scale 553 outcomes, lending further support to emerging studies showing the importance of CD8+ T cells 554

in TB (45,68,74). 555 556

To explore the drivers of granuloma-scale variation within a host, we perform an intra-557 compartmental sensitivity analyses (see Methods) focusing solely on which granuloma-scale 558 parameters are associated with granuloma CFU at day 200. This allows us to identify how 559 granuloma scale parameters may contribute to heterogenous granuloma CFU outcomes within a 560

host when blood and LN parameters are held fixed (PRCC values are given in Supplementary  561 Material). The bottom half of Table 1 lists mechanisms that we identified from both the adaptive 562 and innate immune responses. Multiple parameters that dictate macrophage behavior were 563

identified as key drivers of granuloma CFU. Additionally, adaptive immune response 564 parameters were also associated with reduced granuloma CFU (i.e., Fas:FasL cell death in Table  565 1). 566 567

Altogether, the results from our 'all-in-one' sensitivity analysis as well as our intra-568 compartmental analyses predict that while the adaptive immune response in LNs drive clinical-569 scale outcomes, the innate immune system does play an important role within a host by 570 contributing to heterogeneity of granuloma CFU, as observed within humans and NHPs. 571 572 573 574

Parameters associated with clinical-scale outcomes Description of parameters 'All-in-One' sensitivity analysis

Precursor CD8+ T cell proliferation within the lymph node LN_k14 CD8+ T cell differentiation to CD8+ effector T cell in lymph node LN_k4

Precursor CD4+ T cell proliferation within the lymph node LN_k5 CD4+ T cell differentiation to CD4+ effector T cell in lymph node Parameters associated with granuloma-scale CFU outcomes

Description of parameters Intra-compartment sensitivity analysis k2

Resting macrophage infection rate c9

Likelihood of resting macrophages to phagocytize bacteria N Carrying capacity of intracellular bacteria within macrophages k17

Max rate of infected macrophage death from intracellular bacteria k18 Extracellular bacterial killing by resting macrophages k14a

Fas:FasL induced apoptosis of MI alpha11 IL-4 production from primed T cells 575 The fates of individual granulomas are heterogeneous within hosts 620 621

In both human and NHP studies, individual granulomas within a single host can present a 622 heterogeneous array of morphological, pathological, and immunological outcomes (41,78-80). 623

In NHP studies, even granulomas within active TB monkeys can exhibit sterilization (9,21,81). 624

Similarly, within individual hosts across our virtual population of 500 hosts, we identify a range 625 of granuloma-scale outcomes, from total sterilization to uncontrolled bacterial growth. Figure 5  626 displays individual granuloma CFU trajectories from five representative hosts ranging across 627 different clinical-scale outcomes: TB eliminator, LTBI and active TB, respectively. Within-host 628 variation is apparent in all hosts, but we highlight that host #5 has both sterilized and 629 disseminating granulomas present. Dissemination occurs when bacteria escape one granuloma 630

and seed the formation of another granuloma elsewhere in the lung environment (36). 631

Dissemination granulomas can be identified when a new CFU trajectory begins at any timepoint 632

after the initial infection (c.f. Figure 5B host #5). However, dissemination does not only occur in 633 active TB hosts; we also note a dissemination event occurred in host #3 ( Figure 5B ), a virtual 634

host that is still classified as LTBI according to our established criteria outlined in Figure 3A hosts were simulated to create our population, as shown in Figure 3 . We identified 5 641

representative hosts that exhibited a spectrum of whole-host outcomes (elimination, control and 642 uncontrolled infection outcomes At the granuloma scale, we examine the ratio of pro-and anti-inflammatory cytokines within the 673 granuloma. 674 675

First, we test whether there is a relationship between levels of immune cells in the blood and 676 within the lung. Figure 6A shows an association between lung and blood levels of T cells at day 677 50 for four separate T cell phenotypes (Mtb-specific CD4+ effector, effector memory and Mtb-678 specific CD8+ effector, effector memory) across the 500 virtual hosts. Day 50 was selected as it 679

is typically the height of effector-expansion within in the model, timing that is supported by the 680 NHP granuloma and blood T cell datasets (c.f. Figure 2 ). Each datapoint is colored according to 681 the simulations' clinical outcomes at day 200. Note that there is a relationship between numbers 682 of lung and blood CD4+ effector T cells and CD8+ effector T cells (r = 0.5, p < 0.01 and r = 683 0.61, p < 0.01, respectively). However, by day 200 (Figure 6B) , the time point we use for 684 clinical classification, this relationship between blood and lung numbers is less clear (r = 0.3, p < 685 0.01 and r = 0.14, p < 0.01; for CD4+ and CD8+ effector T cells, respectively). 686 687

Second, we identify a fold-change difference in numbers of lung T cells between days 30 and 40 688 post-infection as indicative of clinical classification 160 simulation days later ( Figure 6C ). 689

Across the four Mtb-specific T cell phenotypes that are recruited into the lung (Mtb-specific 690 CD4+ effector, effector memory and Mtb-specific CD8+ effector, effector memory), virtual 691

hosts that are classified as TB eliminators typically had a larger fold-change difference between 692 days 30 and 40 than did virtual hosts that are classified as active TB or LTBI cases at day 200 693

(Supplementary Material Table 2 shows Vargha and Delaney's A measure for effect size 694 comparisons across all clinical outcomes). Specifically, the median fold change between days 30 695 and 40 of numbers of Mtb-specific CD8+ effector memory T cells in TB eliminator virtual hosts 696 is approximately 10x larger than that of active TB virtual hosts. We observe a similar difference 697 between LTBI and active TB virtual hosts for numbers of Mtb-specific CD4+ effector T cells. 698

These results suggest that numbers of these cell types have a crucial and early role that impacts 699 clinical classifications made over 150 days later. 700 701

Finally, the cytokine profile of granulomas at early time points is indicative of downstream 702 clinical-scale outcomes. Figure 5D shows a three-dimensional scatterplot of pro-and anti-703 inflammatory cytokine concentrations (pg/mL of IFN-g, TNF-a, and IL-10) of every granuloma 704 at day 60 across the 500 virtual hosts. Each granuloma data point is colored according to the 705 classification of the host within which the granuloma resides. Note that a cluster emerges 706

wherein granulomas with high levels of IFN-g, low levels of TNF-α, and low levels of IL-10 are 707

indicative of granulomas that are destined to be within active hosts. By day 200 ( Figure 6E ), this 708 cluster cannot be as easily separated from the other simulations. Taken together, these 709 predictions suggest that the dynamic balance of pro-and anti-inflammatory cytokines across time 710

(83) could obscure this finding for granulomas sampled at later timepoints. 711 712

ESAT-6-specific CD4 T cell responses to aerosol Mycobacterium tuberculosis infection 891 are initiated in the mediastinal lymph nodes. Proceedings of the National Academy of 892 Sciences of the United States of America

Delayed protection by ESAT-6-specific effector 894

CD4+ T cells after airborne M. tuberculosis infection

The evolution of the danger theory

Expert review of clinical immunology

Tumor necrosis factor 900 neutralization results in disseminated disease in acute and latent Mycobacterium 901 tuberculosis infection with normal granuloma structure in a cynomolgus macaque model. 902 Arthritis and Rheumatism

Simian Immunodeficiency Virus-904

T Cell Cytokine Responses in Cynomolgus Macaques with Latent 905

Mycobacterium tuberculosis Infection Are Associated with Timing of Reactivation . The 906

Quantitative 908 comparison of active and latent tuberculosis in the cynomolgus macaque model. Infection 909 and Immunity

Immune biomarkers: the promises and pitfalls of personalized 911 medicine

Mycobacterium 918 tuberculosis-specific CD8+ T cells are functionally and phenotypically different between 919 latent infection and active disease

Empirical Studies Predict Mycobacterium tuberculosis-Specific T Cells as a Biomarker 927 for Infection Outcome

A review of computational and 929 mathematical modeling contributions to our understanding of Mycobacterium tuberculosis 930 within-host infection and treatment. Current Opinion in Systems Biology

Oxygen modulates the effectiveness of granuloma 934 mediated host response to Mycobacterium tuberculosis: A multiscale computational 935 biology approach

Both Pharmacokinetic Variability 937 and Granuloma Heterogeneity Impact the Ability of the First-Line Antibiotics to Sterilize 938

Tuberculosis Granulomas

Frontiers in Pharmacology . 2020. p. 333. 939 Available from

Comparing 941 efficacies of moxifloxacin, levofloxacin and gatifloxacin in tuberculosis granulomas using 942 a multi-scale systems pharmacology approach

Modelling the effects of 945 environmental heterogeneity within the lung on the tuberculosis life-cycle

Modelling the 949 dynamics of tuberculosis lesions in a virtual lung: Role of the bronchial tree in 950 endogenous reinfection

A Model to Predict Cell-Mediated Immune Regulatory 952

Mechanisms During Human Infection with Mycobacterium tuberculosis

Multiscale 955 Computational Modeling Reveals a Critical Role for TNF-Receptor 1 Dynamics in 956 Tuberculosis Granuloma Formation. The Journal of Immunology

A 964 computational model tracks whole-lung Mycobacterium tuberculosis infection and 965 predicts factors that inhibit dissemination

Compartment Hybrid Computational Model Predicts Key 968 Roles for Dendritic Cells in Tuberculosis Infection

Integrating 971 non-human primate, human, and mathematical studies to determine the influence of BCG 972 timing on H56 vaccine outcomes

Lymph nodes-The neglected battlefield 974 in tuberculosis

Initiation of the 977 adaptive immune response to Mycobacterium tuberculosis depends on antigen production 978 in the local lymph node, not the lungs. The Journal of experimental medicine

Heterogeneity in tuberculosis

Identifying control mechanisms of granuloma 984 formation during M. tuberculosis infection using an agent-based model

Tuberculosis: back on the immunologists' agenda

Bcl6-dependent pathways maintain a CD4 T cell population with memory-like properties 990 during tuberculosis

Functional 993 signatures of human CD4 and CD8 T cell responses to Mycobacterium tuberculosis

Defining Memory CD8 T Cell

Mycobacterium tuberculosis-specific CD4 T cells expressing CD153 inversely associate 1000 with bacterial load and disease severity in human tuberculosis

Compartment Hybrid Computational Model Predicts Key 1003 Roles for Dendritic Cells in Tuberculosis Infection

Early changes 1006 by 18Fluorodeoxyglucose positron emission tomography coregistered with computed 1007 tomography predict outcome after Mycobacterium tuberculosis infection in cynomolgus 1008 macaques

Lymph 1010 nodes are sites of prolonged bacterial persistence during Mycobacterium tuberculosis 1011 infection in macaques

Macrophages and control of granulomatous inflammation in 1014 tuberculosis

Infection of 1017 Human Macrophages and Dendritic Cells with <em>Mycobacterium 1018 tuberculosis</em> Induces a Differential Cytokine Gene Expression That Modulates 1019 T Cell Response. The Journal of Immunology

Dendritic Cell 1022 Trafficking and Antigen Presentation in the Human Immune Response to Mycobacterium 1023 tuberculosis

Prominent 1025 role for T cell-derived Tumour Necrosis Factor for sustained control of Mycobacterium 1026 tuberculosis infection

Host 1032 resistance to pulmonary Mycobacterium tuberculosis infection requires CD153 1033 expression

Going beyond gamma for TB protection

Harnessing the heterogeneity of T cell differentiation 1045 fate to fine-tune generation of effector and memory T cells

Compartmental analysis in biology and medicine

Strategies for calibrating models of biology

CaliPro: A Calibration Protocol That Utilizes 1051 Parameter Density Estimation to Explore Parameter Space and Calibrate Complex 1052 Biological Models

Concurrent 1054 infection with Mycobacterium tuberculosis confers robust protection against secondary 1055 infection in macaques

Boosting 1057 BCG with proteins or rAd5 does not enhance protection against tuberculosis in rhesus 1058 macaques. npj Vaccines

A 1060 computational model tracks whole-lung Mycobacterium tuberculosis infection and 1061 predicts factors that inhibit dissemination

A methodology for performing global 1064 uncertainty and sensitivity analysis in systems biology

Single-1067 cell profiling of tuberculosis lung granulomas reveals functional lymphocyte signatures of 1068 bacterial control

Modeling tuberculosis in nonhuman primates. Cold Spring Harbor 1071 Perspectives in Medicine

Why so many 1073 published sensitivity analyses are false: A systematic review of sensitivity analysis 1074 practices. Environmental Modelling & Software

Global sensitivity analysis of 1077 biological multiscale models. Current Opinion in Biomedical Engineering

Controlling the false discovery rate: a practical and powerful 1081 approach to multiple testing

Computational Modeling Predicts IL-10 Control of Lesion Sterilization by 1085

Balancing Early Host Immunity-Mediated Antimicrobial Responses with Caseation 1086 during Mycobacterium tuberculosis Infection . The Journal of 1087 Immunology

CD8 T cells and Mycobacterium tuberculosis infection. Seminars in 1089 Immunopathology

Quantity and Quality of Inhaled Dose Predicts 1092 Immunopathology in Tuberculosis. Frontiers in immunology

Latent Tuberculosis Infection in the United States

The etiology of tuberculosis. Mittheilungen aus dem Kaiserlichen 1098

Heterogeneity in tuberculosis pathology, 1100 microenvironments and therapeutic responses

Lesion-Specific Immune Response in Granulomas of Patients with Pulmonary 1104 Tuberculosis: A Pilot Study

Genomic 1107 diversity in autopsy samples reveals within-host dissemination of HIV-associated 1108 Mycobacterium tuberculosis. Nature medicine

Rhesus 1111 macaques are more susceptible to progressive tuberculosis than cynomolgus macaques: A 1112 quantitative comparison

Mycobacterium tuberculosis infection in cynomolgus macaques

Dynamic balance 1117 of pro-and anti-inflammatory signals controls disease and limits pathology

1120 Digital twins to personalize medicine

Using digital twins in viral infection

A 1126 systematic review of biomarkers to detect active tuberculosis

Update on tuberculosis biomarkers: 1129 from correlates of risk, to correlates of active disease and of cure from disease

1132 Biomarkers of inflammation, immunosuppression and stress with active disease are 1133 revealed by metabolomic profiling of tuberculosis patients

Tuberculosis 1135 biomarkers discovery: developments, needs, and challenges. The Lancet infectious 1136 diseases

Identification of probable early-onset biomarkers for tuberculosis disease progression

Whole-blood flow-1141 cytometric analysis of antigen-specific CD4 T-cell cytokine profiles distinguishes active 1142 tuberculosis from non-active states

Biomarkers of tuberculosis: a research 1144 roadmap

Immunological biomarkers of 1146 tuberculosis

The timing from tuberculosis infection to cavitation. Rassegna di 1148 Patologia dell'Apparato Respiratorio

Neutrophils express pro-and anti-1154 inflammatory cytokines in granulomas from Mycobacterium tuberculosis-infected 1155 cynomolgus macaques

A lung-on-chip 1158 model of early Mycobacterium tuberculosis infection reveals an essential role for alveolar 1159 epithelial cells in controlling bacterial growth

Innate immunity in tuberculosis: host defense vs pathogen evasion

Hematopoietic Stem Cells to Generate Protective Innate Immunity against Tuberculosis

Characterizing the 1170 BCG Induced Macrophage and Neutrophil Mechanisms for Defense Against 1171 Mycobacterium tuberculosis

The key role of exudative lesions and their encapsulation: lessons learned 1177 from the pathology of human pulmonary tuberculosis. Frontiers in microbiology 1178

Neutrophil Dynamics Affect 1180 Mycobacterium tuberculosis Granuloma Outcomes and Dissemination. Frontiers in 1181 immunology

Systems biology predicts that fibrosis in 1184 tuberculous granulomas may arise through macrophage-to-myofibroblast transformation. 1185 PLOS Computational Biology

Assessment of treatment response in 1188 tuberculosis

T cell phenotype in the lung. All granulomas from 500 virtual hosts plotted according to relative 720 concentration TNF, IFN-γ and IL-10 cytokine concentrations (pg/mL) on a log scale (see 721Methods) at day 60 (D) and day 200 (104)). These cells were not included here primarily 793 because datasets were not as readily available or mechanistic functions of these cells within 794 granulomas are not as well characterized. The HostSim modeling framework is flexible and can 795 include these cell types in the future as more data become available about their role in TB 796granulomas. This limitation extends to the LN and blood compartment models as well, where we 797do not capture the events of every cell type involved in Mtb infection (i.e., B cells in the LN). 798Finally, HostSim does not capture physical symptoms of TB disease such as coughing or weight 799 loss. Accordingly, we assumed total lung bacterial burden can be used as a proxy for clinical-800 scale classifications of TB. This assumption is not without precedent. Antibiotic studies in TB 801 frequently use sputum-based assays as a proxy for drug efficacy and assessment of treatment 802 progression in humans (105). Further, NHP studies have shown that total bacterial burden in 803 active TB cases is significantly higher than that of LTBI monkeys, although the same study did 804show a small number of active cases with a bacterial burden similar to that of latent NHPs (21). 805Thus, our cut-off for active TB cases (total lung CFU>10 5 ) in HostSim virtual hosts is unable to 806 capture individuals that may have symptomatic TB but relatively low bacterial burdens. 807However, as more data become available regarding the relationship between symptomatic TB 808 and bacterial burden, future work can integrate those findings into our HostSim framework, 809 perhaps by incorporating a bronchoalveolar lavage (BAL) compartment, for direct comparison to 810 sputum samples. 811 812In conclusion, we utilized a computational modeling framework to better understand the 813 relationship between within-host dynamics and clinical outcomes in TB. We present HostSim: 814 the first whole-host model to track events across granuloma-and host-scales. Using HostSim, 815 we make predictions about relationships between immune cell counts in the blood and lungs and 816 the role of adaptive and innate immune cells in granuloma-scale and host-scale outcomes. In 817 particular, we predict that adaptive immunity generated in lymph nodes drives clinical 818 classifications across hosts in TB, but that innate immunity can drive heterogeneous granuloma 819 outcomes within a single host. We posit that HostSim offers a powerful computational tool that 820can be used in concert with experimental approaches to understand and predict events about 821 various aspects of TB disease and therapeutics.